Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer.
Studies on metastasic lesions from human carcinomas are scarce. Therefore there is a need for such studies to identify the expression of the biological factors that will help in the assessment of the natural history of breast cancer. Here an immunohistochemical study was performed using tissue arrays and specific antibodies against matrix metalloproteinases (MMPs)-1, 2, 7, 9, 11, 13, 14 and tissue inhibitors of metalloproteases (TIMPs)-1, 2 and 3 in 39 patients with breast cancer. Specimens from 39 patients with node-positive carcinomas were examined and the analysis was performed at the central core of the tumour, at the invasive front, and in the metastasic axillary lymph nodes (MALNs). Global expression of MMP-1, 7 and 14, TIMP-1, and 3, were significantly higher at the centre of the tumour compared with the invasive front or the MALNs. Significantly higher expression of MMP-7 and 14, and TIMP-3, by fibroblast-like cells and mononuclear inflammatory cells (MICs) was seen in MALNs. In addition, in the tumour centre, the expression of MMP-11 and TIMP-1 and 2 by MICs, as well as TIMP-2 expression by fibroblast-like cells, were associated significantly with the occurrence of distant metastasis. In contrast, TIMP-3 expression by tumour cells or by fibroblast-like cells in this same tumour locations, as well as TIMP-1 expression by fibroblast-like cells at the invasive front, were associated significantly with poor prognosis. However, the expression of all of these biological factors in MALNs was not associated with the development of distant metastasis. Our data suggest that there is prognostic relevance to the expression of MMPs and TIMPs in the stromal cells of primary tumours, rather than to the expression of these enzymes in MALNs.
García
María Fernanda
MF
Unidad de Investigación, Fundación Hospital de Jove, Gijón-Spain.
González-Reyes
Salomé
S
González
Luis Ovidio
LO
Junquera
Sara
S
Berdize
Nana
N
Del Casar
José Manuel
JM
Medina
María
M
Vizoso
Francisco José
FJ
D001943:Breast Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018270:Carcinoma, Ductal, Breast / Q000201:enzymology* / Q000401:mortality / Q000556:secondary / Q000628:therapy; D016000:Cluster Analysis; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000201:enzymology* / Q000473:pathology; D008207:Lymphatic Metastasis; D053505:Matrix Metalloproteinases, Secreted / Q000032:analysis*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012307:Risk Factors; D017154:Stromal Cells / Q000201:enzymology; D016019:Survival Analysis; D013997:Time Factors; D019714:Tissue Inhibitor of Metalloproteinases / Q000032:analysis*; D016896:Treatment Outcome
D019714:Tissue Inhibitor of Metalloproteinases; D053505:Matrix Metalloproteinases, Secreted
J Pathol. 2004 Apr;202(4):395-402
15095266
Cancer Res. 1992 Apr 1;52(7):1737-43
1551102
J Immunol. 1998 Dec 15;161(12):6845-52
9862716
Clin Cancer Res. 2004 Apr 1;10(7):2289-98
15073104
Br J Cancer. 1999 Mar;79(9-10):1347-55
10188875
Eur J Cancer. 2005 Nov;41(17):2760-8
16256342
J Clin Invest. 1999 May;103(9):1237-41
10225966
Br J Cancer. 2007 Oct 8;97(7):957-63
17848954
Breast Cancer Res. 2000;2(4):252-7
11250717
J Biol Chem. 2001 Jul 6;276(27):25438-46
11320086
Semin Cancer Biol. 2000 Dec;10(6):415-33
11170864
Cancer. 1991 Aug 1;68(3):532-7
2065272
Breast Cancer Res Treat. 2009 Jul;116(1):39-52
19241156
Cell Tissue Kinet. 1990 Sep;23(5):401-8
2245439
Acta Oncol. 1988;27(6A):761-5
3219226
Clin Cancer Res. 2001 Oct;7(10):3289-97
11595727
Annu Rev Cell Dev Biol. 2001;17:463-516
11687497
Blood. 2002 Nov 1;100(9):3361-8
12384438
Anal Quant Cytol Histol. 1993 Feb;15(1):32-8
8385953
J Pathol. 1999 Oct;189(2):161-8
10547569
Nature. 2005 Jul 28;436(7050):518-24
16049480
Cancer Lett. 2006 May 18;236(2):292-301
16019136
J Clin Pathol. 2004 Jul;57(7):746-51
15220369
J Biol Chem. 1995 Mar 10;270(10):5331-8
7890645
Int J Cancer. 1995 Dec 11;63(6):790-3
8847135
Jpn J Cancer Res. 1998 Jan;89(1):27-32
9510472
Gynecol Oncol. 2004 Jan;92(1):47-56
14751137
Cancer Res. 2001 Oct 1;61(19):7091-100
11585740
Cancer Res. 2003 Aug 1;63(15):4671-6
12907648
Breast Cancer Res Treat. 1989 Jan;13(1):17-22
2706325
Br J Cancer. 2003 Oct 6;89(7):1270-5
14520459
FEBS Lett. 2000 Dec 15;486(3):247-51
11119712
Br J Cancer. 2007 Mar 26;96(6):903-11
17342087
Oncogene. 2002 Mar 28;21(14):2245-52
11948407
Endocr Relat Cancer. 2005 Jun;12(2):215-27
15947098
Neoplasia. 2001 Nov-Dec;3(6):459-68
11774028
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
Cancer Lett. 2005 Jan 20;217(2):237-42
15617842
Ann Surg Oncol. 2007 Jun;14(6):1790-800
17342568
Genes Chromosomes Cancer. 1997 Aug;19(4):267-72
9258662
Int J Cancer. 2000 Mar 20;89(2):118-21
10756061
Genes Dev. 2002 Feb 1;16(3):307-23
11825873
J Biol Chem. 1996 Jan 19;271(3):1544-50
8576151
Clin Cancer Res. 1997 Sep;3(9):1623-8
9815852
Crit Rev Immunol. 2005;25(6):493-523
16390324
J Cell Sci. 2001 Jan;114(Pt 1):111-118
11112695
Int J Biol Markers. 1992 Apr-Jun;7(2):107-13
1634821
Nat Rev Cancer. 2002 Mar;2(3):161-74
11990853
Cancer. 1993 Jun 15;71(12):3914-9
8508357
Cancer Cell. 2003 Jun;3(6):537-49
12842083
APMIS. 1999 Jan;107(1):80-5
10190283
J Pathol. 2001 May;194(1):43-50
11329140
Cancer Res. 2004 Mar 1;64(5):1675-86
14996727
Ann Surg Oncol. 1996 Nov;3(6):570-3
8915490
Cancer Res. 1998 Jun 1;58(11):2310-5
9622064
Nat Rev Cancer. 2002 Sep;2(9):657-72
12209155
Invest Ophthalmol Vis Sci. 2000 Sep;41(10):2922-9
10967046
Am J Surg Pathol. 2005 Nov;29(11):1449-55
16224211